Keytruda for ovarian cancer – pro
A 2019 study by Matulonis showed that it single-agent pembrolizumab showed modest activity in patients with ROC. Higher PD-L1 expression was correlated with higher response. NCCN lists it as “useful in certain circumstances”, but they are MMR/MSI or MB+ cancers, not PDL-1 positive.
Matulonis UA et al, Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.Ann Oncol. 2019 Jul 1;30(7):1080-1087
Ovarian Cacner News Today: https://ovariancancernewstoday.com/keytruda-pembrolizumab-for-ovarian-cancer/
NCCN Ovarian 2022 OV-C